SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Introgen Therapeutics -- Ignore unavailable to you. Want to Upgrade?

To: zeta1961 who wrote (694)3/29/2007 1:14:30 PM
From: JibacoaRead Replies (2) | Respond to of 802
 
Yes,according to the FDA,"the lack of a pre-specified primary method for survival analyses renders it difficult to estimate the type I error of this survival analysis," and can't rule out the possibility that the survival difference was due to chance.<g>

On the other hand the 3.9% incidence of CVAs vs. 2.6% in the placebo group was not significant.

DNDN needs to close above $5.35. It seems better to wait until May 15.<g>


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News